Recursion Pharmaceuticals (NASDAQ:RXRX) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a sell rating to a strong sell rating in a research note published on Saturday.

A number of other research firms have also weighed in on RXRX. Morgan Stanley raised their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Trading Up 1.3%

Shares of RXRX opened at $3.22 on Friday. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The stock has a market cap of $1.71 billion, a PE ratio of -3.10 and a beta of 1.03. The firm’s fifty day moving average is $3.32 and its two-hundred day moving average is $3.45. The company has a quick ratio of 5.47, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter last year, the company earned ($0.41) earnings per share. Research analysts forecast that Recursion Pharmaceuticals will post -0.9 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the sale, the director owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 131,937 shares of company stock worth $478,874 over the last quarter. 6.65% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 28.1% in the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after purchasing an additional 2,428 shares during the last quarter. Equitable Holdings Inc. increased its position in shares of Recursion Pharmaceuticals by 7.1% during the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock worth $192,000 after purchasing an additional 2,600 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Recursion Pharmaceuticals by 1.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock worth $954,000 after purchasing an additional 2,753 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Recursion Pharmaceuticals by 29.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after buying an additional 2,883 shares during the period. Finally, Ascent Wealth Partners LLC raised its holdings in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after buying an additional 2,974 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.